Q32 Bio concludes merger deal with Homology Medicines
With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement.
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences’ supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets to treat chronic hepatitis B virus (HBV) in paediatric patients.